KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Buildings: 2009-2011

Historic Buildings for Halozyme Therapeutics (HALO) over the last 2 years, with Mar 2011 value amounting to $1.0 million.

  • Halozyme Therapeutics' Buildings rose 1.52% to $1.0 million in Q1 2011 from the same period last year, while for Mar 2011 it was $1.0 million, marking a year-over-year increase of 1.52%. This contributed to the annual value of $998,368 for FY2010, which is 100.00% down from last year.
  • As of Q1 2011, Halozyme Therapeutics' Buildings stood at $1.0 million, which was up 0.46% from $998,368 recorded in Q4 2010.
  • In the past 5 years, Halozyme Therapeutics' Buildings ranged from a high of $993.0 billion in Q3 2010 and a low of $882,562 during Q1 2009.
  • Over the past 3 years, Halozyme Therapeutics' median Buildings value was $1.0 million (recorded in 2011), while the average stood at $437.6 billion.
  • Data for Halozyme Therapeutics' Buildings shows a peak YoY increase of 106,145,238.43% (in 2010) and a maximum YoY decrease of 100.00% (in 2010) over the last 5 years.
  • Halozyme Therapeutics' Buildings (Quarterly) stood at $981.1 billion in 2009, then crashed by 100.00% to $998,368 in 2010, then grew by 1.52% to $1.0 million in 2011.
  • Its Buildings was $1.0 million in Q1 2011, compared to $998,368 in Q4 2010 and $993.0 billion in Q3 2010.